狼疮试验中临床医生报告结局指标:一个值得解决的问题
本文为观点文章,讨论系统性红斑狼疮(SLE)临床试验中临床医生报告结局指标的演变与局限。现有指标从SLEDAI、BILAG等单一疾病活动指数发展为SRI、BICLA等复合应答定义,但仍存在明显缺陷,确定最佳试验结局指标仍是研究目标。文章分析现有指标优劣,并提出推进终点设计新方法的平台。
要点
- SLE临床试验结局指标从单一疾病活动指数演变为SRI、BICLA等复合应答定义。
- 现有临床医生报告结局指标存在明显缺陷,最佳试验终点仍未确定。
- 文章提出推进终点设计新方法的平台,以改善后续SLE试验的可解释性与成功率。
核心结论
- 现有SLE试验中临床医生报告结局指标存在明显缺陷,定义最佳临床试验结局指标仍是研究目标。
研究设计与样本
- 本文为观点文章,探讨SLE试验中临床医生报告结局指标的优劣并搭建推进终点设计新方法的平台。
主要发现
- SLE试验中临床医生报告结局指标已从SLEDAI、BILAG等单一疾病活动指数演变为基于这些指数的SRI和BICLA等复合应答定义。
- 这些结局指标方法存在明显缺陷,确定SLE最佳临床试验结局指标仍是研究目标。
临床怎么用
- 文章提供平台以推进SLE试验终点设计新方法,旨在改善后续临床试验的可解释性与成功率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) remains a disease of high unmet clinical need. Because of substantial patient heterogeneity, the execution of clinical trials that successfully determine the efficacy of novel therapeutics compared with placebo is a continuous challenge. Clinician-reported outcome measures of treatment response used in SLE trials have evolved from the use of individual disease activity indices, including the SLE Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG), to composite responder definitions such as the SLE Responder Index (SRI) and BILAG-Based Composite Lupus Assessment (BICLA), which are based on these indices. However, these approaches have notable drawbacks and defining the optimal clinical trial outcome measure for SLE remains a research goal. In this Viewpoint, we explore the strengths and limitations of existing indices and composite assessments, illustrating features which should be investigated in future analysis of trial data. Further, we provide a platform from which to advance new approaches to endpoint design, which is crucial to improve the interpretability and success of subsequent clinical trials in SLE.
引用
- Connelly K, Golder V, Kandane-Rathnayake R, et al. Clinician-reported outcome measures in lupus trials: a problem worth solving. Lancet Rheumatol. 2021. PMID: 38287623. doi:10.1016/S2665-9913(21)00119-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。